Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Size & Outlook
- HC Outsourcing
- Clinical & Non-Clinical Outsourcing Services
- Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
- Clinical & Non-Clinical Outsourcing Services
Saudi Arabia Cell Gene Therapy Bioanalytical Testing Services Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the cell & gene therapy bioanalytical testing services market
Saudi Arabia cell & gene therapy bioanalytical testing services market highlights
- The Saudi Arabia cell & gene therapy bioanalytical testing services market generated a revenue of USD 4.8 million in 2023 and is expected to reach USD 6.2 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 3.8% from 2024 to 2030.
- In terms of segment, bioavailability & bioequivalence studies was the largest revenue generating test type in 2023.
- Bioavailability & Bioequivalence Studies is the most lucrative test type segment registering the fastest growth during the forecast period.
Cell & gene therapy bioanalytical testing services market data book summary
| Market revenue in 2023 | USD 4.8 million |
| Market revenue in 2030 | USD 6.2 million |
| Growth rate | 3.8% (CAGR from 2023 to 2030) |
| Largest segment | Bioavailability & bioequivalence studies |
| Fastest growing segment | Bioavailability & Bioequivalence Studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
| Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.9% of the global cell & gene therapy bioanalytical testing services market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia cell & gene therapy bioanalytical testing services market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 5.6 million by 2030.
In 2023, Saudi Arabia accounted for 27.7% of the MEA market. This growth can be attributed to several factors, including an increase in the number of approved gene therapy products & biological therapies and growing public awareness of the advantages of effective biopharmaceutical solutions.
For example, in January 2024, Vertex Pharmaceuticals announced the clearance of CASGEVY (exagamglogene autotemcel [exa-cel]), the first CRISPR/Cas9 gene-edited medicine for treating Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia in patients aged 12 and above.
CASGEVY is the first medication assessed under the SFDA's breakthrough medicines program after the company was given approval by the Saudi SFDA. It is a form of genome editing technology called CRISPR/Cas9-based cellbased gene therapy. CRISPR/Cas9 technology is used to modify the genomes of hematopoietic stem cells in patients.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell & Gene Therapy Bioanalytical Testing Services Market Scope
Cell Gene Therapy Bioanalytical Testing Services Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| IQVIA Holdings Inc | View profile | 87,000 | 2400 Ellis Road, Durham, NC, United States, 27703 | www.iqvia.com |
| Intertek Group PLC | View profile | 44,000 | 33 Cavendish Square, London, United Kingdom, W1G 0PS | www.intertek.com |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | www.syneoshealth.com/ |
| Pharmaron Beijing Co Ltd Ordinary Shares - Class H | View profile | 20,295 | No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, Hong Kong | www.pharmaron.com |
Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook will help companies and investors design strategic landscapes.
Bioavailability & Bioequivalence Studies was the largest segment with a revenue share of 35.42% in 2023.
Horizon Databook has segmented the Saudi Arabia cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
In 2023, Saudi Arabia accounted for 27.7% of the MEA market. This growth can be attributed to several factors, including an increase in the number of approved gene therapy products & biological therapies and growing public awareness of the advantages of effective biopharmaceutical solutions.
For example, in January 2024, Vertex Pharmaceuticals announced the clearance of CASGEVY (exagamglogene autotemcel [exa-cel]), the first CRISPR/Cas9 gene-edited medicine for treating Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia in patients aged 12 and above.
CASGEVY is the first medication assessed under the SFDA's breakthrough medicines program after the company was given approval by the Saudi SFDA. It is a form of genome editing technology called CRISPR/Cas9-based cellbased gene therapy. CRISPR/Cas9 technology is used to modify the genomes of hematopoietic stem cells in patients.
- Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Indication Outlook (Revenue, USD million , 2018-2030)
- Infectious Diseases
- Rare Diseases
- Oncology
- Others
- Neurological disorders
- Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Test Type Outlook (Revenue, USD million , 2018-2030)
- Other test type
- Pharmacodynamics
- Bioavailability & Bioequivalence Studies
- Pharmacokinetics
- Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Product Outlook (Revenue, USD million , 2018-2030)
- Cell Therapy
- Gene-Modified Cell Therapy
- Gene Therapy
- Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Stage of Development Outlook (Revenue, USD million , 2018-2030)
- Clinical
- Non-Clinical
Reasons to subscribe to Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook databook
- Our clientele includes a mix of Cell & Gene Therapy Bioanalytical Testing Services Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Saudi Arabia Cell Gene Therapy Bioanalytical Testing Services Market, 2018-2030 (US$M)
Saudi Arabia cell & gene therapy bioanalytical testing services market statistics, by indication, 2018-2030 (US$M)
